This interview discusses candidate selection, toxicity monitoring, access considerations, and evolving clinical applications of menin inhibitors in acute myeloid leukemia (AML).
Bernard Marini, PharmD, BCOP, FHOPA
Advertisement
Articles by Bernard Marini, PharmD, BCOP, FHOPA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Elevating Precision Medicine in Breast Cancer Care
2
FDA Clears First Single-Inhaler Triple Therapy for Asthma
3
Sonrotoclax Plus Zanubrutinib Achieves Undetectable MRD Rates Above 90% in Frontline CLL/SLL
4
FDA Approves Capvaxive Expanded Indication to Include Children, Adolescents at Increased Risk for Pneumococcal Disease
5